Hong Kong Stock Exchange · Healthcare
Invest in Pak Fah Yeow International stock from India
Indian and foreign residents can buy Pak Fah Yeow International (239) shares directly through Paasa.
By Paasa · Updated
Pak Fah Yeow International at a glance
- Price
- HK$2.48+HK$0.11 (4.64%)
- Market cap
- HK$772.87M
- Day range
- HK$2.48 – HK$2.50
- P/E
- 7.75
- Dividend yield
- 8.06%
- Volume
- 2.50K
- 1 month
- -4.98%
- 6 months
- +4.20%
- YTD
- +4.64%
- 1 year
- +1.22%
- 5 years
- +48.50%
Pak Fah Yeow International statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | HK$213.9M | HK$236.9M | HK$259.3M | HK$147.2M | HK$139.8M |
| Gross profit | HK$133.1M | HK$203.2M | HK$167.6M | HK$74.1M | HK$68.7M |
| Operating income | HK$109.5M | HK$98.3M | HK$143.0M | HK$46.2M | HK$45.0M |
| Net income | HK$91.3M | HK$78.6M | HK$105.0M | HK$30.0M | HK$38.2M |
| Earnings per share | HK$0.29 | HK$0.25 | HK$0.34 | HK$0.10 | HK$0.12 |
| EBITDA | HK$115.4M | HK$105.7M | HK$136.8M | HK$45.9M | HK$54.7M |
| Total assets | HK$828.4M | HK$843.4M | HK$907.5M | HK$823.1M | HK$837.7M |
| Total debt | HK$6.9M | HK$4.2M | HK$4.7M | HK$5.5M | HK$16.2M |
| Cash and short-term investments | HK$344.5M | HK$290.0M | HK$277.6M | HK$180.3M | HK$178.3M |
| Shareholders' equity | HK$722.7M | HK$731.9M | HK$765.2M | HK$707.2M | HK$707.7M |
| Operating cash flow | HK$112.8M | HK$79.0M | HK$147.9M | HK$39.9M | HK$70.4M |
| Free cash flow | HK$112.3M | HK$78.0M | HK$144.8M | HK$39.8M | HK$69.5M |
| Capital expenditure | −HK$437.0K | −HK$937.0K | −HK$3.1M | −HK$156.0K | −HK$820.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in HKD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Beijing Biostar Pharms | 2563.HK | HK$4.71 | HK$1.14B |
| Wenzhou Kangning Hospital | 2120.HK | HK$10.50 | HK$739.19M |
| Lee's Pharmaceutical | 0950.HK | HK$1.20 | HK$706.60M |
| Fusen Pharmaceutical | 1652.HK | HK$0.91 | HK$669.07M |
| Zhongzhi Pharmaceutical | 3737.HK | HK$0.75 | HK$632.81M |
| Guangdong Kanghua Healthcare | 3689.HK | HK$1.78 | HK$595.22M |
| China Biotech Services | 8037.HK | HK$0.55 | HK$531.77M |
| Uni-Bio Science | 0690.HK | HK$0.07 | HK$417.99M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Pak Fah Yeow International from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 239 and buy
Find Pak Fah Yeow International by name or by its ticker, 239, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in Pak Fah Yeow International from India
What Pak Fah Yeow International does
Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and other international territories. Pak Fah Yeow International operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Pak Fah Yeow International stock from India?
Yes. Indian residents and NRIs can buy Pak Fah Yeow International (239) shares directly through Paasa. Pak Fah Yeow International is listed on the Hong Kong Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Pak Fah Yeow International share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$2.48 a share, size the order by the lot, not by the share.
What tax do I pay in India when I sell Pak Fah Yeow International shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
Would my heirs owe estate tax on Pak Fah Yeow International shares?
Hong Kong has no estate duty. That is the source-country side; the shares themselves pass on like any other asset you hold in your own name.